Drug Approval | December 13, 2022
European Commission approves SPEVIGO for generalized pustular psoriasis flares
EC grants conditional marketing authorization based on the EFFISAYIL trial
EC grants conditional marketing authorization based on the EFFISAYIL trial
The hospital is being developed at a cost of more than Rs. 1,575 crore
The Institute will focus on increasing preparedness and laboratory capabilities for identification of novel and unknown zoonotic agents
Soluplus branded excipient play a critical role in enabling the drug development process for poorly soluble active pharmaceutical ingredients
Evaluating Investigational Sitravatinib in combination with Nivolumab for patients with non-squamous non-small cell lung cancer
Presentations include new data on investigational medicines – favezelimab (MK-4280), zilovertamab vedotin (MK-2140) and nemtabrutinib – as well as KEYTRUDA (pembrolizumab) in multiple blood cancers
Application includes data from key phase III trials, including the pivotal MOMENTUM trial, which met all primary and key secondary efficacy endpoints
QS-21 in blockbuster Shingles vaccine, first vaccine approved for Malaria, promising RSV phase III candidate, and Covid-19 applications.
The focus of the companies in this partnership is to synergise capabilities, leverage research and bring innovative products in specific therapeutic areas
South Asia’s largest exhibition for pharma brought together over 50,000 visitors from across the globe
Subscribe To Our Newsletter & Stay Updated
